Results 31 to 40 of about 27,657 (222)

Combined Rosiglitazone and Forskolin Have Neuroprotective Effects in SD Rats after Spinal Cord Injury

PPAR Research, 2018
The peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist rosiglitazone inhibits NF-κB expression and endogenous neural stem cell differentiation into neurons and reduces the inflammatory cascade after spinal cord injury (SCI).
Qing-qi Meng, Wei Lei, Hao Chen, Zhen-cheng Feng, Li-qiong Hu, Xing-liang Zhang, Siming Li   +6 more
doaj   +1 more source

Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?

Scientific Reports, 2017
Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade inflammation, insulin resistance and adipokine ...
Martine C. Morrison, Gopala K. Yakala, Wen Liang, Peter Y. Wielinga, Kanita Salic, Arianne van Koppen, Tushar Tomar, Robert Kleemann, Peter Heeringa, Teake Kooistra   +9 more
doaj   +1 more source

Activation of Peroxisome Proliferator-Activated Receptor γ by Rosiglitazone Inhibits Lipopolysaccharide-Induced Release of High Mobility Group Box 1

Mediators of Inflammation, 2012
Peroxisome proliferator-activated receptors (PPARs) are shown to modulate the pathological status of sepsis by regulating the release of high mobility group box 1 (HMGB1), a well-known late proinflammatory mediator of sepsis.
Jung Seok Hwang, Eun Sil Kang, Sun Ah Ham, Taesik Yoo, Hanna Lee, Kyung Shin Paek, Chankyu Park, Jin-Hoi Kim, Dae-Seog Lim, Han Geuk Seo   +9 more
doaj   +1 more source

Rosiglitazone Attenuates Endothelial Progenitor Cell Apoptosis Induced by TNF-α via ERK/MAPK and NF-κB Signal Pathways

Journal of Pharmacological Sciences, 2011
.: The discovery of endothelial progenitor cells (EPCs) provides us with a novel treatment strategy for complications requiring therapeutic revascularization and vascular repair.
Shengjie Xu, Yanbo Zhao, Lu Yu, Xiaohua Shen, Fang Ding, Guosheng Fu   +5 more
doaj   +1 more source

Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Journal of Lipid Research, 2011
Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglitazone
John S. Millar, Katsunori Ikewaki, LeAnne T. Bloedon, Megan L. Wolfe, Philippe O. Szapary, Daniel J. Rader   +5 more
doaj   +1 more source

Expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in the lung tissue of obese mice and the effect of rosiglitazone on proinflammatory cytokine expressions in the lung tissue [PDF]

Korean Journal of Pediatrics, 2013
PurposeWe investigated the mRNA levels of peroxisome proliferator-activated receptor (PPAR)-α, PPAR-γ, adipokines, and cytokines in the lung tissue of lean and obese mice with and without ovalbumin (OVA) challenge, and the effect of rosiglitazone, a PPAR-
Seung Lok Ryu, Jae Won Shim, Duk Soo Kim, Hye Lim Jung, Moon Soo Park, Soo-Hee Park, Jinmi Lee, Won-Young Lee, Jung Yeon Shim   +8 more
doaj   +1 more source

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome

Iraqi Journal of Pharmaceutical Sciences, 2017
This study was designed to show the advantages of using the combination of metformin and rosiglitazone over using each drug alone in treatment of women with polycystic ovary syndrome (PCOS).Forty four women with PCOS were classified into 3 groups , group
Mohammed A.Taher, Waleed R. Sulaiman, Hillal Y. Al-Khairi   +2 more
doaj   +3 more sources

Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches

BMC Research Notes, 2009
Background A recent and provocative meta-analysis, based on few outcome events, suggested that rosiglitazone increased cardiovascular mortality and myocardial infarction.
Friedrich Jan O, Beyene Joseph, Adhikari Neill KJ   +2 more
doaj   +1 more source

ROSIGLITAZONE

International Journal of Clinical Practice, 2000
SUMMARYRosiglitazone, a potent thiazolidinedione oral antidiabetic agent recently approved in the US, differs structurally from pioglitazone and troglitazone (other approved thiazolidinediones), with greater PPARγ binding affinity and antihyperglycaemic potency in preclinical models.
openaire   +2 more sources

The PPARy ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARy in the subcutaneous adipose tissue

, 2008
PPAR¿ is obligatory for fat mass generation and is thought to determine the amount of TAG stored per fat cell. We investigated whether ligand availability for PPAR¿ is rate limiting in fat mass generation and substrate metabolism.
Kersten, A.H., Bakker, A.H.F., Westerterp, K.R., Joosen, A.M.C.P.   +3 more
core   +1 more source